Nafarelin spray (Synarel) regulates gonadotropin secretion by mimicking the structure of endogenous GnRH and competitively binding to GnRH receptors in the anterior pituitary gland. Synarel demonstrates higher receptor affinity and a longer duration of action. Additionally, its nasal spray formulation offers advantages including convenient administration, stable bioavailability, and relatively mild systemic adverse reactions, leading to its widespread use in gynecological benign tumors and transgender hormone therapy.
Our Products Form
Nafarelin COA
Application in Uterine Fibroids
Uterine fibroids are the most common benign tumors of the female reproductive system, arising from abnormal proliferation of uterine smooth muscle cells. Their pathogenesis is closely associated with long-term stimulation by endogenous estrogen and progesterone. Clinical manifestations mainly include abnormal menstruation, abdominal masses, abdominal pain, and increased leukorrhea. In severe cases, they can cause anemia, infertility, or discomfort due to compression of adjacent organs. As a GnRH agonist, nafarelin spray inhibits gonadotropin secretion and reduces systemic estrogen and progesterone levels, thereby suppressing fibroid growth and alleviating clinical symptoms, making it one of the important pharmacological options for uterine fibroids.
In clinical practice, it is indicated for the following scenarios:
Patients with mild symptoms who decline surgical treatment, especially perimenopausal women. Pharmacological therapy inhibits fibroid growth; following natural menopause and the subsequent decline in hormone levels, fibroids gradually atrophy, avoiding surgical trauma.
Patients with large uterine fibroids (5–10 cm in diameter) posing high surgical risks. Preoperative administration of the product for 3–6 months reduces fibroid volume by 30%–50%, decreases intraoperative bleeding, lowers surgical risks, facilitates surgical manipulation, and minimizes injury to surrounding tissues.
Patients with uterine fibroids complicated by severe anemia. Preoperative use reduces menstrual flow and improves anemia, creating favorable physiological conditions for surgery.
Patients who refuse surgery or have surgical contraindications (e.g., severe cardiac, hepatic, or renal insufficiency). Long-term use controls symptoms and improves quality of life.
Information source: 35 Health – Can Uterine Fibroids Be Treated with Medication?, Can Medication Eliminate Uterine Fibroids?; Minfukang – Leuprorelin Acetate Microspheres for Injection.
Application in Transgender Hormone Therapy
Transgender individuals are those whose gender identity differs from their assigned sex at birth. The two primary groups are transgender women (male assigned at birth, female gender identity) and transgender men (female assigned at birth, male gender identity). The core goal of transgender hormone therapy is to induce the development of secondary sexual characteristics aligned with the individual's gender identity through exogenous hormonal intervention, relieving gender dysphoria and enhancing quality of life. As a GnRH agonist, it suppresses endogenous gonadotropin secretion to establish a favorable endocrine environment, serving as a key adjuvant in transgender hormone therapy, particularly for transgender women.
In transgender women's hormone therapy, it primarily inhibits testicular androgen secretion and reduces systemic testosterone levels, thereby attenuating male secondary sexual characteristics (e.g., prominent Adam's apple, excessive body hair, deep voice) and preparing for subsequent estrogen therapy. Elevated endogenous testosterone counteracts estrogen effects and impairs the development of female secondary sexual characteristics. Thus, GnRH agonist pretreatment is required to reduce testosterone to the normal female range before initiating estrogen therapy. Administered intranasally, nafarelin spray rapidly suppresses pituitary LH and FSH secretion, further inhibiting testicular spermatogenesis and androgen production.
Testosterone levels typically reach the target range within 2–4 weeks. Combined estrogen therapy thereafter effectively promotes breast development, skin softening, fat redistribution, and other female secondary sexual characteristics, while alleviating gender dysphoria and physical discomfort.
Use in transgender men is relatively limited, mainly for patients requiring ovarian function suppression and reduced estrogen secretion. The core of transgender men's hormone therapy is androgen supplementation to induce male secondary sexual characteristics (e.g., body hair growth, increased muscle mass, deepened voice). In patients with hyperactive ovarian function and elevated estrogen levels, short-term the product administration suppresses ovarian estrogen secretion, enhances androgen efficacy, and reduces estrogen-related adverse reactions (e.g., breast tenderness, persistent menstrual bleeding).
Information source: Douyin Encyclopedia – Triptorelin (Drug); Xiaohe Health – What Are the Functions of Nafarelin?
Pharmacokinetics
3.1 Absorption
The product is a nasal formulation absorbed primarily through the nasal mucosa. Abundant mucosal capillaries enable rapid systemic absorption without first-pass metabolism. The drug becomes detectable in plasma within 15–30 minutes of administration, with peak plasma concentrations achieved at 1–2 hours. Nasal patency affects absorption efficiency; nasal inflammation or congestion should be excluded prior to dosing.
Its bioavailability is approximately 20%–40%, far exceeding oral administration (only 1%–5%), as it avoids gastrointestinal degradation and hepatic first-pass metabolism. Food has no significant impact on absorption. Within the therapeutic dose range, peak plasma concentration and area under the curve (AUC) increase linearly with dose, allowing individualized dose titration.
Absorption varies by dosage: peak plasma concentration and AUC rise linearly with increasing dose, indicating dose-dependent absorption within the therapeutic window. Dosing can be adjusted according to disease severity for optimal therapeutic effects.
3.2 Distribution
Following systemic absorption, synarel is widely distributed with a volume of distribution of approximately 20–30 L/kg. Concentrations are higher in reproductive tissues (pituitary gland, ovaries, testes) consistent with its target sites, as well as in the liver and kidneys, supporting metabolic and excretory pathways.
Plasma protein binding is only 20%–30%, with most drug existing in the free active form, resulting in minimal drug–drug interactions and high safety when co-administered with highly protein-bound drugs.
3.3 Metabolism
Nafarelin spray is primarily metabolized in the liver via peptide bond hydrolysis to form inactive metabolites. Intestinal bacteria contribute minimally to metabolism. Metabolites are ultimately excreted from the body.
The plasma elimination half-life is approximately 2–4 hours, with rapid metabolism and low accumulation risk. In patients with hepatic impairment, metabolism is slowed and half-life prolonged, requiring dose reduction and therapeutic drug monitoring.
Unabsorbed drug entering the intestine is hydrolyzed by intestinal bacteria into inactive products and excreted in feces, with negligible impact on overall metabolism.
3.4 Excretion
The drug and its metabolites are excreted mainly via the kidneys (60%–70%) and intestines (30%–40%). Hepatic metabolites and unchanged drug are filtered by the glomeruli and eliminated in urine, with a portion excreted via the intestinal tract.
In renal impairment, excretion is delayed and plasma concentrations increase. Dose reduction and renal/hepatic function monitoring are required for patients with creatinine clearance <30 mL/min. Hemodialysis enhances elimination, supporting dose adjustment as needed.
Within the therapeutic range, excretion rate remains stable and dose-independent, eliminating risks of impaired excretion or accumulation at high doses.
Information source: National Medical Products Administration – Pharmacokinetic Standards; Douyin Encyclopedia – Triptorelin (Drug), Finasteride (A Competitive 5α-Reductase Inhibitor).
I. High-Performance Liquid Chromatography (HPLC)
HPLC is the most commonly used analytical method for nafarelin, particularly for formulation purity testing, aqueous drug concentration determination, and degradation product analysis. The method leverages synarel's physicochemical properties to separate the drug from impurities and degradation products via reversed-phase chromatography, followed by quantitative analysis using various detectors. A typical reversed-phase column is employed with an acetonitrile–water mixture as the mobile phase, and the detection wavelength is set at 225 nm, where synarel exhibits strong absorption.
Studies support three detectors for synarel HPLC analysis: ultraviolet (UV), electrochemical (ECD), and fluorescence (FLD) detectors, all with excellent linear response and consistent results. UV detection is the most convenient for routine analysis, with a limit of detection (LOD) of approximately 1.5 ng. FLD offers the highest sensitivity, with an LOD of 0.6 ng. ECD has an LOD of approximately 2.0 ng. The detector can be selected based on analytical requirements. Additionally, HPLC is used to evaluate the stability of synarel aqueous solutions and monitor its degradation kinetics.
Information source: Taylor & Francis Online – Comparing Electrochemical, Fluorescence, and Ultraviolet Detectors for HPLC Analysis of the Decapeptide, Nafarelin; International Journal of Pharmaceutics.
II. Radioimmunoassay (RIA)
RIA is primarily used for in vivo synarel concentration monitoring, enabling quantitative analysis in plasma or serum for pharmacokinetic studies with a detection limit as low as 50 pg/mL. The method utilizes specific synarel antiserum and radiolabeled synarel as a tracer. Based on specific antigen–antibody binding, free and bound tracers are separated to quantify drug concentrations in samples.
This method requires no complex sample purification, is easy to operate, and delivers high accuracy, with a linear range of 0.050–5.00 ng/mL and excellent correlation. The antiserum shows no cross-reactivity with endogenous GnRH, ensuring high specificity. In vivo studies confirm strong consistency between RIA, HPLC, and HPLC-radiochemical detection, effectively supporting synarel pharmacokinetic and toxicological research.
Information source: Sci-Hub – Radioimmunoassay of Nafarelin ((6-(3-(2-Naphthyl)-D-alanine))-Luteinizing Hormone-Releasing Hormone) in Plasma or Serum.
Management of Hypersensitivity Reactions
Rare severe cutaneous adverse reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) may occur, presenting with rash, blisters, mucosal erosion, fever, etc. Administration must be permanently discontinued, and emergency treatment initiated immediately.
Information source: Pfizer – SYNAREL® Warnings and Precautions.
FAQ
What are the side effects of Synarel nasal spray?
+
-
Common side effects include acne, changes in breast size, and menstrual (period) bleeding. Call your health care provider right away if you have depression, seizures, or problems with your vision. Synarel is a nasal spray.
Do you get your period on Synarel?
+
-
In any case, you can expect this bleeding to stop by itself. After the first two months of treatment with SYNAREL, you can expect a decrease in menstrual flow, and your periods may stop altogether. However, if you miss one or more doses of SYNAREL, you may continue to experience vaginal bleeding.
Hot Tags: nafarelin spray, China nafarelin spray manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, Ipamorelin Pill, glp1 shot, etelcalcetide structure
